Innovent's IBI3001 Shows 30.2% Response Rate in Phase 1 Solid Tumor Study

• Innovent Biologics on Oct. 25, 2026, reported Phase 1 results for cancer treatment IBI3001 presented at the ESMO Congress.
• The experimental therapy showed antitumor activity across several advanced cancers in heavily pretreated patients, including lung and pancreatic cancers.
• Safety was manageable, with no treatment-related deaths; one participant permanently discontinued treatment because of a treatment-related adverse event.
• IBI3001 has advanced to Phase 1b dose optimization to further evaluate its safety and efficacy in patients with treatment-resistant cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610250200PR_NEWS_USPR_____CN80333) on October 25, 2026, and is solely responsible for the information contained therein.